Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

CorMedix (CRMD) Long-Term Investments (2024 - 2025)

CorMedix (CRMD) has disclosed Long-Term Investments for 2 consecutive years, with $23.8 million as the latest value for Q4 2025.

Quarterly Long-Term Investments rose 22581.9% to $23.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.8 million through Dec 2025, up 22581.9% year-over-year, with the annual reading at $23.8 million for FY2025, 22581.9% up from the prior year.
Long-Term Investments hit $23.8 million in Q4 2025 for CorMedix, up from $22.9 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $23.8 million in Q4 2025 to a low of $105000.0 in Q4 2024.